Literature DB >> 1859041

Current concepts in ocular allergy.

M H Friedlaender1.   

Abstract

Ocular allergy is commonly encountered by the allergist, general physician, and ophthalmologist. Diagnosis can usually be made by history, especially a history of itching and an allergic background. The diagnosis can be confirmed by skin testing, in vitro testing, and conjunctival scrapings to look for eosinophils. Once the diagnosis is made, a decision can be reached as to whether treatment is necessary. Often, supportive treatment, or removal of the allergen is preferred. When pharmacologic treatment is necessary, it is advisable to choose a benign form of therapy such as topical vasoconstrictor-antihistamine eyedrops or cromolyn sodium. Topical steroids are rarely necessary and should be used with great caution since they can induce serious sight threatening complications. If topical steroids are required, the patient should be monitored by an ophthalmologist.

Entities:  

Mesh:

Year:  1991        PMID: 1859041

Source DB:  PubMed          Journal:  Ann Allergy        ISSN: 0003-4738


  11 in total

Review 1.  Allergic ocular disease. A review of pathophysiology and clinical presentations.

Authors:  L Bielory; P E Goodman; E M Fisher
Journal:  Clin Rev Allergy Immunol       Date:  2001-04       Impact factor: 8.667

2.  Double-masked, randomized, parallel-group study comparing olopatadine 0.1% ophthalmic solution with cromolyn sodium 2% and levocabastine 0.05% ophthalmic preparations in children with seasonal allergic conjunctivitis.

Authors:  Giorgio Ciprandi; Darell Turner; Robert D Gross
Journal:  Curr Ther Res Clin Exp       Date:  2004-03

Review 3.  Therapeutic options in ocular allergic disease.

Authors:  M Hingorani; S Lightman
Journal:  Drugs       Date:  1995-08       Impact factor: 9.546

Review 4.  Drug treatment of allergic conjunctivitis. A review of the evidence.

Authors:  G Ciprandi; S Buscaglia; P M Cerqueti; G W Canonica
Journal:  Drugs       Date:  1992-02       Impact factor: 9.546

5.  Protective effects of deflazacort on allergen-specific conjunctival challenge.

Authors:  G Ciprandi; S Buscaglia; A Iudice; G P Pesce; M Bagnasco; G W Canonica
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

6.  Measurement of IL-4 in tears of patients with seasonal allergic conjunctivitis and vernal keratoconjunctivitis.

Authors:  H Fujishima; T Takeuchi; N Shinozaki; I Saito; K Tsubota
Journal:  Clin Exp Immunol       Date:  1995-11       Impact factor: 4.330

7.  Levocabastine eye drops in the treatment of vernal conjunctivitis.

Authors:  F Goes; S Blockhuys; M Janssens
Journal:  Doc Ophthalmol       Date:  1994       Impact factor: 2.379

8.  N-acetyl-aspartyl glutamic acid (NAAGA) topical eyedrops in the treatment of giant papillary conjunctivitis (GPC).

Authors:  F Meijer; K Pogany; J H Kok; A Kijlstra
Journal:  Doc Ophthalmol       Date:  1993       Impact factor: 2.379

9.  Pharmacokinetics of cetirizine in tear fluid after a single oral dose.

Authors:  Lucia Grumetto; Gilda Cennamo; Antonio Del Prete; Maria I La Rotonda; Francesco Barbato
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

10.  A review of the tolerability and safety of levocabastine eye drops and nasal spray. Implications for patient management.

Authors:  P H Howarth
Journal:  Mediators Inflamm       Date:  1995       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.